Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MITCHELL SHIFFMAN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1497847461
CMS profile
294197
Location
NEWPORT NEWS, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$105,797.15

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MITCHELL SHIFFMAN

NPI 1497847461 · CMS profile ID 294197

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

NEWPORT NEWS, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $105,797.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $15.1105/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777431 CMS
Gilead Sciences, Inc. $20.9105/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777433 CMS
Gilead Sciences, Inc. $25.9605/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864576 CMS
Gilead Sciences, Inc. $118.1705/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864578 CMS
Gilead Sciences, Inc. $720.7505/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864580 CMS
Gilead Sciences, Inc. $724.8005/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864582 CMS
Gilead Sciences, Inc. $846.6605/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864584 CMS
Gilead Sciences, Inc. $6.8805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777423 CMS
Gilead Sciences, Inc. $58.7805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777425 CMS
Gilead Sciences, Inc. $138.0005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777427 CMS
Gilead Sciences, Inc. $65.9205/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864572 CMS
Gilead Sciences, Inc. $75.4705/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864574 CMS
AstraZeneca Pharmaceuticals LP $28.5705/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105783536 CMS
Novo Nordisk Inc $2,712.5005/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096931637 CMS
Exelixis Inc. $136.8004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138562368 CMS
FUJIFILM Healthcare Americas Corporation $86.5604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146124966 CMS
Intercept Pharmaceuticals, Inc. $114.5004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113639593 CMS
Intercept Pharmaceuticals, Inc. $1,267.5004/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113639595 CMS
Intercept Pharmaceuticals, Inc. $4,960.0004/16/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113639597 CMS
Intra-Sana Laboratories $750.0004/16/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138620030 CMS
Gilead Sciences, Inc. $4,930.0004/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133605272 CMS
Gilead Sciences, Inc. $86.5504/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777421 CMS
Gilead Sciences, Inc. $96.6104/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864570 CMS
Gilead Sciences, Inc. $67.9804/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777419 CMS
Gilead Sciences, Inc. $42.1704/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777417 CMS
Gilead Sciences, Inc. $23.8604/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864566 CMS
Gilead Sciences, Inc. $26.0004/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864568 CMS
Ipsen Biopharmaceuticals, Inc $2,523.0004/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091967009 CMS
Gilead Sciences, Inc. $110.7104/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777415 CMS
Intercept Pharmaceuticals, Inc. $1,240.0003/25/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113639591 CMS
Intra-Sana Laboratories $1,500.0003/21/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138620028 CMS
Alnylam Pharmaceuticals Inc. $122.5803/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125854717 CMS
FUJIFILM Healthcare Americas Corporation $99.6403/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146124946 CMS
Gilead Sciences, Inc. $49.9903/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133777413 CMS
Gilead Sciences, Inc. $298.5003/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864560 CMS
Gilead Sciences, Inc. $350.0003/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864562 CMS
Gilead Sciences, Inc. $520.7003/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133864564 CMS
Intra-Sana Laboratories $1,500.0002/27/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138620026 CMS
Novo Nordisk Inc $2,325.0002/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097693981 CMS
Intra-Sana Laboratories $120.1002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138620024 CMS
Genentech USA, Inc. $207.1802/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133074051 CMS
Genentech USA, Inc. $152.0702/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133074055 CMS
Genentech USA, Inc. $138.6402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133074059 CMS
Genentech USA, Inc. $2,939.5202/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133074063 CMS
Genentech USA, Inc. $682.8802/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133074067 CMS
Gilead Sciences, Inc. $3,240.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133605280 CMS
HISTOSONICS,INC. $142.3002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154803275 CMS
Intra-Sana Laboratories $1,500.0001/25/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138620022 CMS
Exact Sciences Corporation $92.0701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114895159 CMS
Exact Sciences Corporation $98.6601/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114895162 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $113,684.18 126
PY2020 $30,712.26 40
PY2021 $42,774.50 70
PY2022 $73,255.38 94
PY2023 $75,582.83 77
PY2024 $105,797.15 155
PY2025 $193,208.17 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,198,804.14 205
PY2024 Principal investigator $575,196.17 103
PY2023 Principal investigator $184,035.14 23
PY2022 Principal investigator $209,840.21 32
PY2021 Principal investigator $417,616.19 215
PY2020 Principal investigator $424,274.57 73
PY2019 Recipient $1,052.00 1
PY2019 Principal investigator $1,008,010.51 123

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $1,337.85 12/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254307
Principal investigator 1 Gilead Sciences, Inc. $3,600.00 12/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206440
Principal investigator 1 Gilead Sciences, Inc. $1,739.00 12/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206448
Principal investigator 1 Ipsen Bioscience Inc. $1,075.00 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546917
Principal investigator 1 Ipsen Bioscience Inc. $691.40 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546919
Principal investigator 1 Ipsen Bioscience Inc. $325.30 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546921
Principal investigator 1 Ipsen Bioscience Inc. $1,308.20 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546923
Principal investigator 1 Ipsen Bioscience Inc. $421.20 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546925
Principal investigator 1 Ipsen Bioscience Inc. $1,655.45 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546927
Principal investigator 1 Ipsen Bioscience Inc. $2,965.95 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546929
Principal investigator 1 Ipsen Bioscience Inc. $4,250.00 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546931
Principal investigator 1 Ipsen Bioscience Inc. $4,006.00 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546933
Principal investigator 1 Ipsen Bioscience Inc. $998.00 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546935
Principal investigator 1 Ipsen Bioscience Inc. $2,000.00 12/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546937
Principal investigator 1 Madrigal Pharmaceuticals $4,588.25 12/11/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253834
Principal investigator 1 Madrigal Pharmaceuticals $9,511.04 12/11/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253838
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 12/10/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223289518
Principal investigator 1 Ipsen Bioscience Inc. $2,471.00 12/04/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546915
Principal investigator 1 Madrigal Pharmaceuticals $4,939.38 12/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253316
Principal investigator 1 Madrigal Pharmaceuticals $300.00 12/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253340
Principal investigator 1 Madrigal Pharmaceuticals $600.00 12/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253344
Principal investigator 1 Madrigal Pharmaceuticals $1,570.14 12/02/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253204
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $45,556.47 12/01/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC D
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223288977
Principal investigator 1 Madrigal Pharmaceuticals $11,295.06 11/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252866
Principal investigator 1 Madrigal Pharmaceuticals $2,000.00 11/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252875
Principal investigator 1 Madrigal Pharmaceuticals $1,000.00 11/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252878
Principal investigator 1 Madrigal Pharmaceuticals $1,000.00 11/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252882
Principal investigator 1 Madrigal Pharmaceuticals $85.05 11/17/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252661
Principal investigator 1 Madrigal Pharmaceuticals $707.50 11/17/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252666
Principal investigator 1 Ipsen Pharma SAS $2,000.00 11/14/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184307045
Principal investigator 1 Ipsen Pharma SAS $800.00 11/14/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184307047
Principal investigator 1 Gilead Sciences, Inc. $4,800.00 11/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206432
Principal investigator 1 Madrigal Pharmaceuticals $4,939.38 11/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252400
Principal investigator 1 Madrigal Pharmaceuticals $1,885.82 11/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252404
Principal investigator 1 Gilead Sciences, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203948
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203955
Principal investigator 1 Gilead Sciences, Inc. $3,843.04 10/24/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203965
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $114.75 10/17/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC D
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223287119
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 10/09/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251412
Principal investigator 1 Ipsen Bioscience Inc. $116.00 10/03/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546911
Principal investigator 1 Ipsen Bioscience Inc. $116.00 10/03/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546913
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 10/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250940
Principal investigator 1 Madrigal Pharmaceuticals $14,000.00 10/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250952
Principal investigator 1 Madrigal Pharmaceuticals $1,128.87 10/03/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251030
Principal investigator 1 Madrigal Pharmaceuticals $2,600.00 09/29/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250763
Principal investigator 1 Genentech, Inc. $1,500.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581826
Principal investigator 1 Genentech, Inc. $2,000.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581830
Principal investigator 1 Genentech, Inc. $1,000.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581834
Principal investigator 1 Genentech, Inc. $3,000.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581838
Principal investigator 1 Genentech, Inc. $1,950.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581846
Principal investigator 1 Genentech, Inc. $3,000.00 09/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581853
Principal investigator 1 Gilead Sciences, Inc. $2,230.00 09/23/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206425
Principal investigator 1 Madrigal Pharmaceuticals $4,588.25 09/23/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250530
Principal investigator 1 Madrigal Pharmaceuticals $4,588.25 09/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250111
Principal investigator 1 Madrigal Pharmaceuticals $1,200.00 09/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250115
Principal investigator 1 Madrigal Pharmaceuticals $49,924.38 09/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250119
Principal investigator 1 Madrigal Pharmaceuticals $300.00 09/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250123
Principal investigator 1 Madrigal Pharmaceuticals $100.00 09/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250135
Principal investigator 1 Gilead Sciences, Inc. $2,993.71 09/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206418
Principal investigator 1 Ipsen Bioscience Inc. $2,000.00 09/12/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546907
Principal investigator 1 Ipsen Bioscience Inc. $600.00 09/12/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546909
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 09/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249878
Principal investigator 1 Madrigal Pharmaceuticals $6,597.63 09/05/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249724
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 09/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249386
Principal investigator 1 Madrigal Pharmaceuticals $2,469.69 08/26/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249062
Principal investigator 1 Ipsen Bioscience Inc. $3,008.00 08/21/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546905
Principal investigator 1 Madrigal Pharmaceuticals $9,334.45 08/21/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248836
Principal investigator 1 Gilead Sciences, Inc. $3,353.00 08/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206412
Principal investigator 1 Gilead Sciences, Inc. $10,820.00 08/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206403
Principal investigator 1 Madrigal Pharmaceuticals $4,237.12 08/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248060
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/01/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223283507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,750.00 08/01/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223283509
Principal investigator 1 Madrigal Pharmaceuticals $2,627.64 07/31/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247686
Principal investigator 1 Genentech, Inc. $800.00 07/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581843
Principal investigator 1 Genentech, Inc. $4,000.00 07/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581849
Principal investigator 1 Gilead Sciences, Inc. $5,637.00 07/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206394
Principal investigator 1 Ipsen Bioscience Inc. $3,008.00 07/22/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546903
Principal investigator 1 Madrigal Pharmaceuticals $12,927.60 07/18/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248247265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,417.34 07/18/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223282822
Principal investigator 1 Gilead Sciences, Inc. $1,069.20 07/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203931
Principal investigator 1 Gilead Sciences, Inc. $2,474.95 07/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203940
Principal investigator 1 Ipsen Bioscience Inc. $3,008.00 07/10/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546901
Principal investigator 1 Madrigal Pharmaceuticals $1,570.14 07/10/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246757
Principal investigator 1 Gilead Sciences, Inc. $1,530.00 07/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206369
Principal investigator 1 Gilead Sciences, Inc. $288.00 07/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206376
Principal investigator 1 Gilead Sciences, Inc. $170.10 07/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206386
Principal investigator 1 Madrigal Pharmaceuticals $5,097.33 07/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246591
Principal investigator 1 Gilead Sciences, Inc. $78.30 07/02/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203925
Principal investigator 1 Madrigal Pharmaceuticals $1,337.85 06/24/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246072
Principal investigator 1 Madrigal Pharmaceuticals $1,885.82 06/24/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246077
Principal investigator 1 Madrigal Pharmaceuticals $3,771.64 06/24/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246089
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,952.36 06/20/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223281692
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 06/20/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223281694
Principal investigator 1 Ipsen Bioscience Inc. $2,500.00 06/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546895
Principal investigator 1 Ipsen Bioscience Inc. $4,250.00 06/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546897
Principal investigator 1 Ipsen Bioscience Inc. $998.00 06/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546899
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 06/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245811
Principal investigator 1 Madrigal Pharmaceuticals $2,469.69 06/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245819
Principal investigator 1 Madrigal Pharmaceuticals $250.00 06/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245827
Principal investigator 1 Madrigal Pharmaceuticals $7,578.23 06/19/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245830
Principal investigator 1 Madrigal Pharmaceuticals $28.35 06/19/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245842
Principal investigator 1 Madrigal Pharmaceuticals $7,808.50 06/19/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245847
Principal investigator 1 Madrigal Pharmaceuticals $500.00 06/19/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245850
Principal investigator 1 Gilead Sciences, Inc. $5,689.00 06/17/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206361
Principal investigator 1 Madrigal Pharmaceuticals $3,949.92 06/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245656
Principal investigator 1 Madrigal Pharmaceuticals $2,118.56 06/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245333
Principal investigator 1 Madrigal Pharmaceuticals $5,255.28 06/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245341
Principal investigator 1 Gilead Sciences, Inc. $300.00 06/10/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206341
Principal investigator 1 Gilead Sciences, Inc. $1,310.00 06/10/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206353
Principal investigator 1 Ipsen Pharma SAS $1,500.00 06/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184307041
Principal investigator 1 Ipsen Pharma SAS $13,500.00 06/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184307043
Principal investigator 1 Madrigal Pharmaceuticals $3,246.08 06/05/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244908
Principal investigator 1 Madrigal Pharmaceuticals $200.00 06/05/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244912
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203888
Principal investigator 1 Gilead Sciences, Inc. $500.00 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203896
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,750.00 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280658
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280660
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280662
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,357.44 06/04/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280664
Principal investigator 1 Gilead Sciences, Inc. $7,750.00 06/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206318
Principal investigator 1 Gilead Sciences, Inc. $2,140.00 06/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206325
Principal investigator 1 Gilead Sciences, Inc. $1,020.00 06/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,996.27 06/02/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280564
Principal investigator 1 Madrigal Pharmaceuticals $1,227.15 05/29/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244769
Principal investigator 1 Madrigal Pharmaceuticals $4,116.95 05/29/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244773
Principal investigator 1 Madrigal Pharmaceuticals $7,373.84 05/28/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,400.00 05/28/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280434
Principal investigator 1 Ipsen Bioscience Inc. $2,377.00 05/22/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546893
Principal investigator 1 Madrigal Pharmaceuticals $4,496.32 05/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244248
Principal investigator 1 Madrigal Pharmaceuticals $2,500.00 05/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244252
Principal investigator 1 Madrigal Pharmaceuticals $1,750.00 05/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244255
Principal investigator 1 Madrigal Pharmaceuticals $2,400.00 05/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244259
Principal investigator 1 Madrigal Pharmaceuticals $2,000.00 05/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,147.85 05/21/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280012
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 05/21/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280014
Principal investigator 1 Gilead Sciences, Inc. $8,653.00 05/20/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206301
Principal investigator 1 Gilead Sciences, Inc. $4,110.00 05/20/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206310
Principal investigator 1 Ipsen Pharma SAS $1,933.88 05/16/2025 Non-covered Recipient Entity
Sc Liver Research Consortium
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307593
Principal investigator 1 Madrigal Pharmaceuticals $5,005.40 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243695
Principal investigator 1 Madrigal Pharmaceuticals $7,633.04 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243700
Principal investigator 1 Madrigal Pharmaceuticals $2,500.00 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243704
Principal investigator 1 Madrigal Pharmaceuticals $1,750.00 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243707
Principal investigator 1 Madrigal Pharmaceuticals $3,130.72 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243715
Principal investigator 1 Madrigal Pharmaceuticals $2,000.00 05/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243719
Principal investigator 1 Ipsen Bioscience Inc. $1,500.00 05/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546891
Principal investigator 1 Gilead Sciences, Inc. $5,132.16 05/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203904
Principal investigator 1 Ipsen Pharma SAS $11,866.40 05/07/2025 Non-covered Recipient Entity
Sc Liver Research Consortium
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307581
Principal investigator 1 Ipsen Pharma SAS $12,948.00 05/07/2025 Non-covered Recipient Entity
Sc Liver Research Consortium
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307583
Principal investigator 1 Ipsen Pharma SAS $12,948.00 05/07/2025 Non-covered Recipient Entity
Sc Liver Research Consortium
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307585
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 05/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223279100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,032.77 05/07/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223279102
Principal investigator 1 Genentech, Inc. $1,600.00 05/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581803
Principal investigator 1 Genentech, Inc. $65.00 05/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581807
Principal investigator 1 Genentech, Inc. $8,000.00 05/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211581811
Principal investigator 1 Ipsen Bioscience Inc. $9,000.00 05/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546883
Principal investigator 1 Ipsen Bioscience Inc. $4,736.00 05/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546885
Principal investigator 1 Ipsen Bioscience Inc. $12,500.00 05/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546887
Principal investigator 1 Ipsen Bioscience Inc. $13,000.00 05/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546889
Principal investigator 1 Ipsen Bioscience Inc. $2,377.00 04/28/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546881
Principal investigator 1 Madrigal Pharmaceuticals $1,885.82 04/28/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242794
Principal investigator 1 Madrigal Pharmaceuticals $250.00 04/26/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242647
Principal investigator 1 Gilead Sciences, Inc. $3,843.04 04/25/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203918
Principal investigator 1 Madrigal Pharmaceuticals $11,631.19 04/24/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242619
Principal investigator 1 Madrigal Pharmaceuticals $438.00 04/23/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242564
Principal investigator 1 Madrigal Pharmaceuticals $1,200.00 04/23/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242568
Principal investigator 1 Gilead Sciences, Inc. $39,295.00 04/22/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206293
Principal investigator 1 Ipsen Bioscience Inc. $2,377.00 04/15/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546879
Principal investigator 1 Madrigal Pharmaceuticals $6,895.98 04/11/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242319
Principal investigator 1 Madrigal Pharmaceuticals $8,992.64 04/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241774
Principal investigator 1 Madrigal Pharmaceuticals $5,097.33 04/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241777
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 03/13/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240883
Principal investigator 1 Madrigal Pharmaceuticals $21,982.16 03/13/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,985.75 03/12/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223276337
Principal investigator 1 Madrigal Pharmaceuticals $7,882.92 03/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240265
Principal investigator 1 Madrigal Pharmaceuticals $4,296.65 03/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240269
Principal investigator 1 Ipsen Bioscience Inc. $2,471.00 03/04/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546877
Principal investigator 1 Madrigal Pharmaceuticals $1,050.00 02/14/2025 Non-covered Recipient Entity
BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248239770
Principal investigator 1 Madrigal Pharmaceuticals $40,141.42 02/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239092
Principal investigator 1 Madrigal Pharmaceuticals $4,496.32 02/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239096
Principal investigator 1 Madrigal Pharmaceuticals $15,765.84 02/06/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239100
Principal investigator 1 Ipsen Bioscience Inc. $2,471.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546853
Principal investigator 1 Ipsen Bioscience Inc. $4,000.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546855
Principal investigator 1 Ipsen Bioscience Inc. $2,736.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546857
Principal investigator 1 Ipsen Bioscience Inc. $12,500.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546859
Principal investigator 1 Ipsen Bioscience Inc. $17,000.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546861
Principal investigator 1 Ipsen Bioscience Inc. $1,598.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546863
Principal investigator 1 Ipsen Bioscience Inc. $333.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546865
Principal investigator 1 Ipsen Bioscience Inc. $222.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546867
Principal investigator 1 Ipsen Bioscience Inc. $359.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546869
Principal investigator 1 Ipsen Bioscience Inc. $7,000.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546871
Principal investigator 1 Ipsen Bioscience Inc. $1,250.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546873
Principal investigator 1 Ipsen Bioscience Inc. $2,303.00 02/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546875
Principal investigator 1 Madrigal Pharmaceuticals $23,782.16 01/30/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238863
Principal investigator 1 Ipsen Bioscience Inc. $58.00 01/29/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546849
Principal investigator 1 Ipsen Bioscience Inc. $2,400.00 01/29/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546851
Principal investigator 1 Ipsen Bioscience Inc. $2,471.00 01/21/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546847
Principal investigator 1 Madrigal Pharmaceuticals $240,347.58 01/16/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238503
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 01/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208537
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 01/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208546
Principal investigator 1 Gilead Sciences, Inc. $3,750.00 01/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208553
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 01/15/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208560
Principal investigator 1 Ipsen Bioscience Inc. $7,553.00 01/07/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546843
Principal investigator 1 Ipsen Bioscience Inc. $447.00 01/07/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546845
Principal investigator 1 Madrigal Pharmaceuticals $3,407.04 01/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237873
Principal investigator 1 Madrigal Pharmaceuticals $9,032.85 01/03/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238008